A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2018

At a glance

  • Drugs Alirocumab (Primary)
  • Indications Hypercholesterolaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms ODYSSEY-Combo-I
  • Sponsors Sanofi
  • Most Recent Events

    • 01 Jun 2018 Results of a pooled analysis of 5 studies (LONG TERM, HIGH FH, FH I, FH II and COMBO) assessing the safety and efficacy of Alirocumab, published in the Diabetes Therapy
    • 02 Feb 2018 Results (n=3499) of pooled analysis assessing efficacy and safety from FH I,FH II, LONG TERM, HIGH FH, COMBO I studies, published in the American Journal of Cardiology.
    • 15 Nov 2017 Results of pooled analysis from ten ODYSSEY trials assessing characteristics of patients with less than 5% LDL-C reduction presented at the 90th Annual Scientific Sessions of the American Heart Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top